Avalyn Pharma, Inc. (AVLN)

37.39 +1.95 (+5.50%) USD  |  NASDAQ  |  Sep 04, 16:00
37.00 -0.39 (-1.04%) After-Hours: 20:00
More

Avalyn Pharma Shareholders Equity (Quarterly) : 398.35M for June 30, 2026

Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for AVLN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2026. Start Trial.
Date Value
June 30, 2026 398.35M
Date Value
March 31, 2026 107.98M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
Filana Therapeutics, Inc. 63.61M
CorMedix, Inc. 460.83M
Eloxx Pharmaceuticals, Inc. 46.42M
Cannabis Global, Inc. -4.772M
Breakthrough Chemistry, Inc. 0.8373M

Shareholders Equity (Quarterly) Related Metrics

Total Assets (Quarterly) 425.45M
Total Liabilities (Quarterly) 27.10M
Debt to Equity Ratio 0.043
Current Ratio 33.10
Net Debt Paydown Yield -0.20%